Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain

BACKGROUND: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Sp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sanchez-de la Rosa, Rainel, Sabater, Eliazar, Casado, Miguel A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer 2013
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3651713/
https://ncbi.nlm.nih.gov/pubmed/23647721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-1991-3-13
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller